cyclosporine has been researched along with Cancer of Prostate in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, SM; Cho, EA; Chun, JN; Jeon, JH; Kim, SY; Kim, YS; Lee, DY; Lee, S; Park, EJ; Park, HH; Park, S; So, I | 1 |
| Ide, H; Ishiguro, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Zheng, Y | 1 |
| Hinds, T; Periyasamy, S; Sanchez, ER; Shemshedini, L; Shou, W | 1 |
| Fu, Y; Jiang, S; Wang, Z; Zhang, Y; Zu, Y | 1 |
| Anidjar, M; Chevalier, S; Cury, FL; Hamel, L; Luz, M; Rocha, J; Scarlata, E | 1 |
| Cho, NH; Chun, JN; Jeon, JH; Kim, IG; Kim, IS; Kim, SH; Kim, SY; Kim, TW; Lee, CR; Park, EJ; Park, S; So, I | 1 |
| Lutterbach, J; Momm, F; Pflieger, D | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Auborn, KJ; Carter, TH; Evans, JF; Rabinowitz, D; Savino, JA | 1 |
| Periyasamy, S; Sanchez, ER; Shou, W; Tillekeratne, MP; Warrier, M | 1 |
| Baumgartner, G; Hamilton, G; Schirmböck, M; Sherwood, ER; Thalhammer, T; Theyer, G | 1 |
| Barry, JM; Batiuk, TD; Bennett, WM; Meyer, MM; Norman, DJ; Tolzman, D | 1 |
| Pollard, M | 1 |
| Filo, RS; Ha, R; Jindal, RM; Leapman, SB; Milgrom, MM; Pescovitz, MD | 1 |
2 trial(s) available for cyclosporine and Cancer of Prostate
| Article | Year |
|---|---|
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
Topics: Adenoma, Bile Duct; Age Factors; Azathioprine; Cyclosporine; Follow-Up Studies; Humans; Immunosuppression Therapy; Incidence; Kidney Transplantation; Lymphoma; Male; Muromonab-CD3; Neoplasms; Prostatic Neoplasms; Retrospective Studies; Skin Neoplasms; Thyroid Neoplasms | 1993 |
12 other study(ies) available for cyclosporine and Cancer of Prostate
| Article | Year |
|---|---|
Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK‑dependent manner.
Topics: Bayes Theorem; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Androgen; Repressor Proteins; Transcription Factors | 2023 |
The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclosporine; Disease Progression; Humans; Male; Mice; Neoplasm Invasiveness; NFATC Transcription Factors; Prostatic Neoplasms; Tacrolimus; Xenograft Model Antitumor Assays | 2015 |
FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
Topics: Androgens; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Male; Metribolone; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tacrolimus; Tacrolimus Binding Proteins | 2010 |
Involvement of mitochondrial permeability transition pore opening in 7-xylosyl-10-deacetylpaclitaxel-induced apoptosis.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Cyclosporine; Cytosol; Drug Evaluation, Preclinical; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2011 |
Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men.
Topics: Animals; Bone Neoplasms; Carcinoma; Cell Line, Tumor; Cyclosporine; Disease Models, Animal; Dogs; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Transplantation; Prostatic Neoplasms | 2012 |
Cyclosporin A suppresses prostate cancer cell growth through CaMKKβ/AMPK-mediated inhibition of mTORC1 signaling.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cell Proliferation; Cyclosporine; Enzyme Activation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Phosphatidylinositols; Prostatic Neoplasms; Proteins; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Paraneoplastic erythroderma in a prostate cancer patient.
Topics: Aged; Biomarkers, Tumor; Biopsy; Cyclosporine; Dermatitis, Exfoliative; Diagnosis, Differential; Humans; Male; Paraneoplastic Syndromes; Prostate-Specific Antigen; Prostatic Neoplasms; Skin | 2002 |
Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.
Topics: Apoptosis; Benzylamines; Calcium; Calcium Signaling; Chelating Agents; Cyclosporine; Cytosol; Egtazic Acid; Endoplasmic Reticulum; Enzyme Inhibitors; Female; Humans; Indoles; Male; Prostatic Neoplasms; Sulfonamides; Thapsigargin; Uterine Cervical Neoplasms | 2006 |
The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
Topics: Androgens; Biological Transport; Cell Division; Cell Line, Tumor; Cell Nucleus; Cyclophilins; Cyclosporine; Dihydrotestosterone; Humans; Immunophilins; Ligands; Male; Nuclear Proteins; Peptidyl-Prolyl Isomerase F; Phosphoprotein Phosphatases; Prostatic Neoplasms; Receptors, Androgen; Tacrolimus; Tacrolimus Binding Proteins; Transcription, Genetic | 2007 |
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cell Division; Cyclosporine; Doxorubicin; Drug Resistance; Humans; Male; Membrane Glycoproteins; Phenotype; Prostatic Neoplasms; Rhodamine 123; Rhodamines; Tamoxifen; Tumor Cells, Cultured; Verapamil | 1993 |
Enhancement of metastasis of prostate adenocarcinoma cells by immune-suppressive cyclosporine A.
Topics: Adenocarcinoma; Animals; Cyclosporine; Immunosuppressive Agents; Lung Neoplasms; Lymphatic Metastasis; Male; Prostatic Neoplasms; Rats; Rats, Wistar; Specific Pathogen-Free Organisms | 1997 |
Prostate-specific antigen values and their clinical significance in renal transplant recipients.
Topics: Adult; Aged; Creatinine; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Proteinuria; Retrospective Studies | 1998 |